Home > Riviste > Minerva Pediatrics > Fascicoli precedenti > Minerva Pediatrics 2021 October;73(5) > Minerva Pediatrics 2021 October;73(5):452-9

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi PROMO
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo
Share

 

REVIEW   

Minerva Pediatrics 2021 October;73(5):452-9

DOI: 10.23736/S2724-5276.21.05939-5

Copyright © 2021 EDIZIONI MINERVA MEDICA

lingua: Inglese

Comparison of the effect of fluticasone combined with salmeterol and fluticasone alone in the treatment of pediatric asthma

Huling CAO 1, Junhua GU 2, Juan DAI 1, Guihong YANG 1, Hui TANG 1, Aiming DING 3

1 Pediatric Ward, the Second Affiliated Hospital of Nantong University, Nantong City, China; 2 Department of Radiology, the Second Affiliated Hospital of Nantong University, Nantong City, China; 3 Department of Nursing, the Second Affiliated Hospital of Nantong University, Nantong City, China



INTRODUCTION: A systematic review and meta-analysis was performed to investigate the effect of fluticasone + salmeterol and fluticasone alone in the treatment of pediatric asthma.
EVIDENCE ACQUISITION: Studies meeting specific selection criteria were selected from online databases, including Pubmed, Embase, and the Cochrane Library. The quality of randomized controlled trials was assessed using the Cochrane Library. Weighted mean difference (WMD) and 95% CI were used to evaluate the effect size of continuous variables, while rate ratio (RR) and 95% CI were used for dichotomous variables.
EVIDENCE SYNTHESIS: A total of 11 studies, including 8272 pediatric asthma patients, were included in this meta-analysis. Among these, 4133 patients were in the salmeterol + fluticasone group. The changes in forced expiratory volume in 1 second in children with asthma in the salmeterol + fluticasone and fluticasone alone groups were significantly different (fixed effects model, WMD=3.26, 95% CI: 1.52-5.00, P=0.0002). Asthma exacerbation between two groups were significantly different (fixed effects model, RR=0.85, 95% CI: 0.73-0.98, Z=2.18, P=0.03). There was no difference in the incidence of adverse events between salmeterol + fluticasone and fluticasone alone in the treatment of pediatric asthma (P>0.05). When the control group was treated with double dose fluticasone, the difference of changes in FEV1 and asthma exacerbation in children with asthma between the two groups was not significant.
CONCLUSIONS: The efficacy of salmeterol + fluticasone is better than fluticasone alone, and the efficacy of salmeterol + fluticasone is equal to doubling the dose of fluticasone in the treatment of pediatric asthma.


KEY WORDS: Fluticasone; Salmeterol xinafoate; Meta-analysis; Pediatrics

inizio pagina